Background:Acute Promyelocytic Leukemia is a myeloid dissease wich is informed to be more frequent in latinos, but there is few epidemiological data about these.This is a review of 19 Hospitals in different states of Mexico, from Northern to South of Mexico.A retrospective study of all cases of acute promyelocytic leukemia treated from 2007‐2018, a total of 324 cases.Aims:Our Aim objective is to know our overall survival of the population with acute promyelocyic leukemia treated in different institutions in MexicoSecondary objectives: Learn about treatment used in theses different institutions, and mortality related.Methods:We perform a rtrospective analysis from 2007‐2018, a total of 324 cases diagnose with acute promylocytic leukemia, inform consent was perform in all casesResults:The Median age 36 years old (range 15‐73), relation male:female 163:161. Infection at diagnosis 12%(39cases), DIC 31% (102 cases), Hemorrages 21%, CNS:8cases, Gastrointestinal 18cases, urinary tract:15, skin:28 cases. Leucocite at diagnosis median of 22.3 (1.0‐450), Platelets median of 40 (2‐318), Fybrogen median 190 range22‐825, TTPa 32 seconds (28‐255).Risk at diagnosis: low 36%, intermediate:24%, high risk:40%. ATRA used in 94% of the cases and antracyclines used Daunorrubicin 58%, and Idarrubicin 42%. Mortality of 14%. ATRA syndrome 16% in the Daunorrubicin arm and 20% idarrubicinSummary/Conclusion:We show that patient treated with daunorrubicin had a better survival during the induction, with a overall mortality of 14% in the induction related mortality.Median age of diagnosis 36 years old.In Mexico there is no ATO, so we still treating patients with chemotherapy and a maintenance of 2 years afther 3 consolidations, the most used atracycline is daunorrubicin. There was no difference between the ATRA syndrome in both antracyclines.

No abstract